Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD of VYNE Therapeutics Inc. from 2015 to Q2 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
VYNE Therapeutics Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from 2015 to Q2 2025.
- VYNE Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Jun 2025 was -$5.76M, a 38.7% increase year-over-year.
- VYNE Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Jun 2025 was -$38.5M, a 35.1% decline year-over-year.
- VYNE Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$39.8M, a 40.2% decline from 2023.
- VYNE Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$28.4M, a 22.5% decline from 2022.
- VYNE Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$23.2M, a 68.3% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)